DelveInsight’s “Sickle Cell Disease Pipeline Insights 2025” report provides comprehensive insights about 55+ companies and 60+ drugs in the Sickle Cell Disease Competitive landscape.

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

In the absence of any marketed drugs, investors are set to focus on BEAM's pipeline updates when it reports first-quarter 2025 earnings.

On CRSP's first-quarter 2025 earnings call, investors will likely focus on the sales numbers of its new gene therapy, Casgevy.

Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Like many government institutions, the National Institutes of Health (NIH) faces big budget cuts and a dramatic restructuring ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...